Adrenal Disorder Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

The adrenal glands — paired endocrine organs sitting atop each kidney — produce hormones essential for stress response, blood pressure regulation, electrolyte balance, and androgen production. The adrenal cortex produces glucocorticoids (cortisol), mineralocorticoids (aldosterone), and androgens (DHEA, androstenedione), while the adrenal medulla produces catecholamines (adrenaline and noradrenaline). Disorders of the adrenal glands span a wide clinical spectrum from life-threatening adrenal insufficiency to hormonally active tumours causing hypertension, weight gain, or masculinisation.

Adrenal disorders requiring treatment include: Addison's disease (primary adrenal insufficiency — cortisol and aldosterone deficiency from adrenal gland destruction, most commonly autoimmune); Cushing's syndrome (glucocorticoid excess — from ACTH-secreting pituitary adenoma causing Cushing's disease, adrenal adenoma/carcinoma, or ectopic ACTH production); primary hyperaldosteronism (Conn's syndrome — aldosterone excess causing hypertension and hypokalaemia, most commonly from adrenal adenoma or bilateral hyperplasia); phaeochromocytoma (catecholamine-secreting chromaffin cell tumour causing episodic hypertension, headache, and sweating); congenital adrenal hyperplasia (CAH — enzyme deficiency causing cortisol deficiency and androgen excess); and adrenal incidentalomas (adrenal masses found incidentally on imaging requiring biochemical characterisation and oncological assessment).

Treatment is highly specific to the underlying disorder. Medical management with hormone replacement is the cornerstone of adrenal insufficiency treatment. Surgical adrenalectomy is curative for most functional adrenal tumours. Targeted pharmacotherapy controls hormone excess while awaiting surgery or in inoperable cases. Adrenal disorders require specialist endocrinological management given the complexity of hormonal assessment and the risk of adrenal crisis — a life-threatening emergency — in patients with adrenal insufficiency.

Addison's disease (primary adrenal insufficiency) is treated with lifelong daily oral hydrocortisone (cortisol replacement, 15-25 mg/day in divided doses) and fludrocortisone (aldosterone replacement, 50-200 mcg/day). Stress dosing — tripling the hydrocortisone dose during illness, surgery, or severe physical stress — and carrying an emergency hydrocortisone injection kit are essential safety requirements. Adrenal crisis requires immediate emergency IV or IM hydrocortisone injection (100 mg) with IV saline resuscitation.

Cushing's syndrome treatment depends on the underlying cause. Pituitary-dependent Cushing's disease (70% of cases) is treated by trans-sphenoidal surgical resection of the causative pituitary microadenoma, achieving remission in 60-80% of cases at specialist centres. Adrenal Cushing's from a benign adenoma is treated by laparoscopic adrenalectomy, curative in over 95% of cases. Adrenocortical carcinoma requires open surgical resection (often radical) with adjuvant mitotane therapy. Pharmacological cortisol suppression with metyrapone, ketoconazole, osilodrostat, or pasireotide (for pituitary Cushing's) is used while awaiting surgery or in inoperable cases. Primary hyperaldosteronism (Conn's syndrome) from a unilateral adenoma is treated by laparoscopic adrenalectomy; bilateral hyperplasia is managed with mineralocorticoid receptor antagonists (spironolactone or eplerenone). Phaeochromocytoma requires laparoscopic adrenalectomy after mandatory pre-operative alpha-blockade (phenoxybenzamine or doxazosin for 10-14 days) to prevent intraoperative hypertensive crisis.

All patients with confirmed biochemical adrenal insufficiency require lifelong hormone replacement therapy — this is not an elective treatment but a physiological necessity for survival. Patients with Addison's disease require lifetime hydrocortisone and fludrocortisone replacement regardless of age, comorbidities, or surgical fitness. Adrenal crisis is a medical emergency that must be treated immediately with parenteral hydrocortisone regardless of the clinical setting.

Surgical adrenalectomy is indicated for confirmed functional adrenal tumours causing hormonal excess (Cushing's syndrome, Conn's syndrome, phaeochromocytoma), for adrenal masses with imaging features suggesting malignancy (size above 4 cm, heterogeneous appearance, elevated unenhanced Hounsfield Units above 10 on CT), and for adrenocortical carcinoma. Fitness for laparoscopic adrenalectomy requires adequate cardiorespiratory reserve and systematic pre-operative biochemical optimisation — particularly alpha-adrenergic blockade before phaeochromocytoma resection. Very large tumours (above 8-10 cm) or those with local invasion suggesting carcinoma require open surgery.

For Addison's disease, hydrocortisone replacement should mimic the physiological cortisol circadian rhythm — the largest dose is taken in the morning, with a smaller afternoon dose, and no evening dose (to avoid insomnia). Modified-release hydrocortisone (Plenadren) provides once-daily dosing with a pharmacokinetic profile more closely approximating normal cortisol secretion and may improve fatigue and quality of life compared to conventional twice-daily dosing. Fludrocortisone is titrated to maintain normal blood pressure, electrolytes, and plasma renin activity. All patients require adrenal crisis education, a steroid emergency card, and a vial of emergency hydrocortisone for self-administration.

Laparoscopic transperitoneal or retroperitoneoscopic adrenalectomy is the gold-standard surgical approach for most adrenal tumours. The retroperitoneoscopic approach (posterior retroperitoneoscopic adrenalectomy — PRA) avoids the peritoneal cavity, reduces visceral organ handling, and enables faster recovery — it is the preferred approach for most benign adrenal tumours up to 8 cm at specialist centres. Open adrenalectomy via lateral flank or anterior transabdominal approach is reserved for very large tumours, suspected malignancy requiring en-bloc resection, or prior abdominal surgery creating extensive adhesions. Pharmacological adrenal cortex suppression agents — metyrapone, ketoconazole, osilodrostat (Isturisa), and levoketoconazole — are used pre-operatively or in surgically inoperable Cushing's syndrome.

Selecting the most appropriate Adrenal Disorder Treatment approach requires a structured assessment of patient-specific factors. The treating specialist evaluates disease severity, prior treatment history, comorbidities, and patient preferences before recommending a specific protocol. Combination approaches are often more effective than monotherapy — integrating pharmacological, procedural, or rehabilitative elements to address multiple disease mechanisms simultaneously. Dose or intensity is titrated incrementally based on clinical response, tolerability, and objective outcome measures. In patients with refractory disease or inadequate response to first-line protocols, escalation to higher-intensity or specialist-delivered treatment options is indicated. Multidisciplinary team (MDT) review ensures that surgical, medical, and allied health perspectives are integrated into the final management plan, particularly for complex or high-risk cases where multiple treatment pathways are viable and the risk-benefit balance requires careful deliberation.

Hormone replacement therapy for Addison's disease is life-saving and life-sustaining — without cortisol and fludrocortisone replacement, adrenal insufficiency is fatal within days. With proper replacement and emergency dose adjustment education, patients with Addison's disease achieve normal or near-normal quality of life and life expectancy, with modern hydrocortisone replacement achieving cortisol exposures within physiological range.

Laparoscopic adrenalectomy for unilateral aldosterone-producing adenoma (Conn's syndrome) achieves blood pressure normalisation without antihypertensive medication in 40-70% of patients at 12 months, with significant blood pressure improvement in an additional 25-30%. Cure of hypokalaemia occurs in over 95% of cases. For phaeochromocytoma, complete surgical resection with adequate pre-operative alpha-blockade has near-universal biochemical cure rates and resolution of hypertensive crises. For adrenal Cushing's syndrome from benign adenoma, laparoscopic adrenalectomy achieves biochemical and clinical remission in over 95% of patients — with resolution of weight gain, hypertension, diabetes, and mood symptoms over 12-18 months as cortisol excess resolves.

Adrenal crisis is the most serious risk in patients with adrenal insufficiency — it can be triggered by any intercurrent illness, surgery, or physiological stress and presents with severe hypotension, vomiting, and confusion. Without immediate hydrocortisone and IV saline, adrenal crisis is fatal. Education of patients, family members, and treating physicians regarding crisis recognition and emergency treatment is the primary safety intervention.

Laparoscopic adrenalectomy carries complication rates of 3-5% for major complications: haemorrhage from the adrenal vein or adjacent vessels (1-2%), injury to adjacent organs including the spleen, liver, or kidney (0.5-1%), pneumothorax, and conversion to open surgery (1-3%). For phaeochromocytoma resection specifically, intraoperative hypertensive crisis — from catecholamine release during tumour manipulation before ligation of the adrenal vein — occurs in 5-15% of cases despite adequate pre-operative alpha-blockade, requiring intraoperative phentolamine or nitroprusside management by experienced anaesthetists. Patients undergoing bilateral adrenalectomy for refractory Cushing's syndrome develop permanent adrenal insufficiency requiring lifelong replacement and carry risk of Nelson's syndrome — pituitary ACTH-producing macroadenoma enlargement following loss of cortisol negative feedback — in 20-30% of cases.

Patients with Addison's disease require indefinite specialist endocrinology follow-up, typically annually once established on stable replacement. Annual review addresses hydrocortisone dose optimisation, fludrocortisone titration using lying and standing blood pressure, and plasma renin activity measurement. Quality-of-life assessment using validated tools identifies patients who might benefit from DHEA replacement or modified-release hydrocortisone.

After laparoscopic adrenalectomy for a cortisol-producing adenoma, patients who developed contralateral adrenal suppression from chronic cortisol excess require post-operative hydrocortisone cover and gradual weaning over 6-18 months as the remaining adrenal gland recovers function, monitored by early morning cortisol and ACTH stimulation tests. After adrenalectomy for phaeochromocytoma, 24-hour urine or plasma metanephrine measurement at 6 weeks, 6 months, and annually thereafter monitors for biochemical recurrence. For aldosterone-producing adenoma, blood pressure and electrolyte normalisation is confirmed at 1 and 3 months post-surgery, with antihypertensive medications weaned if blood pressure allows.

Medical management of Addison's disease — hydrocortisone and fludrocortisone — is inexpensive: annual medication costs are £100-£200 in the UK, and $200-$500 in the US. Specialist endocrinology consultations and biochemical monitoring add $500-$2,000 annually in the US. Laparoscopic adrenalectomy in the United States costs $20,000-$40,000 including hospital, surgeon, and anaesthesia. In the United Kingdom under private care, $12,000-£20,000.

At endocrine surgery centres in India — Apollo Hospitals, Medanta, AIIMS Delhi — laparoscopic adrenalectomy costs $5,000-$10,000 including comprehensive pre-operative assessment, surgery, and post-operative care. Thailand (Bumrungrad International) charges $8,000-$15,000. The specialist endocrine surgical expertise available at leading Indian hospitals, many with surgeons trained in Western centres, is fully equivalent to Western standards. Medical tourism for planned adrenalectomy (excluding emergency adrenal crisis management) offers 50-70% cost savings at JCI-accredited facilities.

For adrenal insufficiency, there is no alternative to hormone replacement — it is physiologically essential and life-sustaining. For Cushing's syndrome from ACTH-secreting pituitary tumours, medical therapy (metyrapone, ketoconazole, osilodrostat) achieves cortisol normalisation in 50-75% of patients as a bridge to surgery or in cases not amenable to surgical resection, with limited side effect profiles compared to older agents. Radiotherapy (stereotactic radiosurgery) offers an alternative to surgical resection for residual or recurrent pituitary adenoma after trans-sphenoidal surgery, achieving remission in 50-70% of patients at 3-5 years.

For primary hyperaldosteronism from bilateral adrenal hyperplasia — where surgery is not indicated — mineralocorticoid receptor antagonists (spironolactone or eplerenone) provide effective long-term blood pressure control and potassium normalisation. Spironolactone is generally preferred for efficacy, though its anti-androgenic side effects (gynaecomastia in men, menstrual irregularity) lead some patients to prefer eplerenone or a potassium-sparing diuretic combination. For adrenal incidentalomas not meeting criteria for resection, annual CT imaging and repeat biochemical assessment at 1 year are the standard surveillance strategy.